The geochronology and origin of mantle sources for late cenozoic intraplate volcanism in the frontal part of the Arabian plate in the Karacadag neovolcanic area of Turkey. Part 2. The results of geochemical and isotope (Sr-Nd-Pb) studies

A geochemical and isotope-geochemical (Sr-Nd-Pb) study has been carried out for the Karacadag neovolcanic area, which is situated within the frontal part of the Arabian plate. The obtained data and the results of petrological modeling show that the petrogenesis of parental magmas in the Karacadag neovolcanic area involved two compositionally different mantle sources; one consisted of garnet-bearing peridotites of the asthenosphere mantle and the other was spinel-bearing peridotites of the enriched subcontinental lithosphere mantle. During early stages in the evolution of the magmatic system, deep-seated asthenospheric magmas were ascending to the surface while intensively interacting with the melts that had been generated at upper mantle depths. The interaction gradually diminished, so that the later effusive rocks mostly have compositions that are similar to those of the primitive asthenospheric magmas. It is shown that a significant (up to 17-18 wt % of the mantle melt) assimilation of crustal material could take place only during the initial phases of the magmatism. Periodic replenishment of the magma chambers by primitive magmas, which resulted in an observable high degree of homogeneity in the composition of young effusive rocks, was also of importance in the petrogenesis of lavas during the evolution of volcanic activity

Geology, geochemistry and Re-Os geochronology of the Jurassic Zeybek volcanogenic massive sulfide deposit (Central Pontides, Turkey)

Located in the north of Anatolia, the Pontide Orogenic Belt hosts Turkey's most important volcanogenic massive sulfide (VMS) deposits. Studies completed in the last ten years have discovered new massive sulfide deposits in the Central Pontide zone. The Zeybek VMS deposit is one of these newly-discovered deposits found in the Central Pontides. This deposit is associated with the Çangaldağ Metamorphic Complex occurring as east-west-striking tectonic slices. The Çangaldağ Metamorphic Complex is an allochthonous mass of metavolcanic, metavolcaniclastic and metaclastic rocks in the form of imbricated tectonic slices. Zeybek massive sulfide deposit is located within metaclastic rocks intercalated with mafic sills or lava flows in this complex. The major ore mineral paragenesis in the Zeybek VMS deposit comprises pyrite, chalcopyrite and sphalerite, with lower amounts of bornite, covelline, chalcocite and magnetite. With thirty thousand meters of drilling in the mineralized area, 20 million ton resources with 0.32 wt% Cu were determined. According to the wall-rock mineralization relationships, mineralization style and ore geochemistry of the Zeybek VMS mineralization, it is similar to a mafic-siliciclastic type volcanogenic massive sulfide formation. Re-Os geochronologic studies of chalcopyrites from the Cu-rich massive ore samples obtained a 178 ± 2.2 Ma (MSWD: 4.1) 187Re/188Os against 187Os/188Os isochron. Geochemical and isotopical age data associated with the Zeybek VMS deposit indicate that the mineralization occurred in an arc-back arc tectonic environment, which developed in Middle Jurassic age intra-ocean as a result of the closure of north-ward subduction that resulted the closure of the Tethys ocean. © 2019 Elsevier B.V.National Basic Research Program of China (973 Program): 2018YFC0604006 National Natural Science Foundation of China: 41572077We would like to thank to all MTA staff who assigned in this project. We would like to thank to editor Franco Pirajno and reviewers for their constructive criticism contributions. This study has been prepared based on the project of ‘Polimetal ore exploration of Kastamonu province surounding in General Directorate of Mineral Resource and Exploration (MTA); with the project number (2013/2019)-32-13-05. Within the scope of this project we thank geological engineers Kenan ÇOŞKUN, Aysun SÖZCÜ, Aydın Olcay ÇOLAKOĞLU, Serdar KESKİN, Furkan ERDEM, Özkan YILDIRIM, Buğra GÖKÇEOĞLU, Ercüment AYSERT and Mehmet KÖKSAL, Onur TİRYAKİ for field and laboratory studies. We are grateful to geological engineers Füsun NİĞDELİ, Mustafa TOKOĞLU, and Yusuf Mehmet ERDEM and mining engineer İsmail ÖKSÜZ for completing solid model and feasibility studies related to mineralization. The National Key Research and Development Program of China ( 2018YFC0604006 ) and National Natural Science Foundation of China ( 41572077 ) have supported this study Re/Os age analizes. Appendix

The geochronology and origin of mantle sources for late cenozoic intraplate volcanism in the frontal part of the Arabian plate in the Karacadag neovolcanic area of Turkey. Part 1. The results of isotope-geochronological studies

This paper considers results from isotope-geochronological (K-Ar) studies of the products of Neogene-Quaternary volcanism in the Karacadag area, which is situated within the northern frontal part of the Arabian plate. It was found that magmatic activity has been evolving at this location for at least the last 11-10 Myr and was distinctly discrete in character. Three stages of volcanism have been identified: (I) Early or Miocene, similar to 11-6.7 Ma; (II) Middle or Pliocene-Early Quaternary, 4-1 Ma; and (III) Late or Late Quaternary, 0.4-0.1 Ma. The most recent manifestations of magmatic activity in the region date back to about 100000 years ago

Analysis of acute myelogenous leukemia: Preparation of samples for genomic and proteomic analyses

During the last decade, several large clinical studies have demonstrated that analysis of chromosomal abnormalities is an essential basis for therapeutic decisions in patients with acute myelogenous leukemia (AML), and cytogenetic studies should now be regarded as mandatory both for routine treatment and as a part of clinical investigations in AML. However, new techniques for detailed genetic characterization and analysis of gene expression as well as protein modulation will become important in the further classification of AML subsets and the development of risk-adapted therapeutic strategies. In this context, we emphasize the importance of population-based clinical studies as a basis for future therapeutic guidelines. Such studies will then require the inclusion of patients at small clinical centers without specialized hematological research laboratories. To document a high and uniform quality of the laboratory investigations, it will be necessary to collect material for later analysis in selected laboratories. In this article, we describe current methods for collection of biological samples that can be used for later preparation of DNA, RNA, and proteins. With the use of gradient-separated AML cells, it should be possible to establish the necessary techniques for collection and handling of biological samples even at smaller centers, and complete collections from all included patients should then be possible even in population-based clinical studies

metastatic, trastuzumab-naive breast cancer: real-life practice outcomes

PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.C1 [Esin, Ece; Oksuzoglu, B.; Erdur, E.; Demirci, U.] Univ Hlth Sci, Dept Med Oncol, Dr AY Ankara Oncol Educ & Res Hosp, Ankara, Turkey.[Bilici, A.] Medipol Univ, Int Hlth Ctr, Dept Med Oncol, Istanbul, Turkey.[Cicin, I.; Kostek, O.] Trakya Univ, Dept Med Oncol, Edirne, Turkey.[Kaplan, M. A.] Dicle Univ, Dept Med Oncol, Fac Med, Diyarbakir, Turkey.[Aksoy, S.; Aktas, B. Y.] Hacettepe Univ, Dept Med Oncol, Fac Med, Ankara, Turkey.[Ozdemir, O.; Alacacioglu, A.] Izmir KC Univ, Ataturk Educ & Res Hosp, Dept Med Oncol, Izmir, Turkey.[Cabuk, D.] Kocaeli Univ, Fac Med, Dept Med Oncol, Izmit, Turkey.[Sumbul, A. T.] Baskent Univ, Dept Med Oncol, Adana Hosp, Adana, Turkey.[Sakin, A.] Istanbul Okmeydani Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey.[Paydas, S.; Yetisir, E.] Cukurova Univ, Dept Med Oncol, Fac Med, Adana, Turkey.[Er, O.; Basaran, G.] Acibadem MAA Univ, Acibadem Maslak Hosp, Dept Med Oncol, Istanbul, Turkey.[Korkmaz, T.; Oyan, B.] Acibadem MAA Univ, Acibadem Altunizade Hosp, Dept Med Oncol, Istanbul, Turkey.[Yildirim, N.] Dr Ersin Arslan Training & Res Hosp, Dept Med Oncol, Gaziantep, Turkey.[Sakalar, T.] Erciyes Univ, Dept Med Oncol, Fac Med, Kayseri, Turkey.[Demir, H.] Kayseri Educ & Res Hosp, Univ Hlth Sci, Dept Med Oncol, Kayseri, Turkey.[Artac, M.; Karaagac, M.] Necmettin Erbakan Univ, Meram Med Fac, Dept Med Oncol, Konya, Turkey.[Harputluoglu, H.; Bilen, E.] Inonu Univ, Dept Med Oncol, Turgut Ozal Med Ctr, Malatya, Turkey.[Degirmencioglu, S.] Pamukkale Univ, Dept Med Oncol, Fac Med, Denizli, Turkey.[Aliyev, A.] Bezmialem Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey.[Cil, T.; Olgun, P.] Adana City Hosp, Univ Hlth Sci, Dept Med Oncol, Adana, Turkey.[Gumusay, O.] Gaziosmanpasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkey.[Demir, A.] Univ Hlth Sci, Dept Med Oncol, Istanbul Okmeydani Educ & Res Hosp, Istanbul, Turkey.[Tanrikulu, E.; Yumuk, P. F.] Marmara Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey.[Imamoglu, Inanc] Univ Hlth Sci, Ankara Diskapi Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Cetin, B.] RTE Univ, Dept Med Oncol, Fac Med, Rize, Turkey.[Haksoyler, V.] Univ Hlth Sci, Diyarbakir GY Educ & Res Hosp, Dept Med Oncol, Diyarbakir, Turkey.[Karadurmus, N.; Erturk, I.] Univ Hlth Sci, Gulhane Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Evrensel, T.; Yilmaz, H.] Uludag Univ, Dept Med Oncol, Fac Med, Bursa, Turkey.[Beypinar, I.] Afyon Kocatepe Univ, Dept Med Oncol, Fac Med, Afyon, Turkey.[Kocer, M.] Isparta SD Univ, Dept Med Oncol, Fac Med, Isparta, Turkey.[Pilanci, K. N.] Univ Hlth Sci, Dept Med Oncol, Haseki Educ & Res Hosp, Istanbul, Turkey.[Seker, M.; Urun, Y.] Ankara Bayindir Hosp, Dept Med Oncol, Ankara, Turkey.[Urun, Y.] Ankara Univ, Dept Med Oncol, Fac Med, Ankara, Turkey.[Yildirim, N.; Eren, T.] Univ Hlth Sci, Numune Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey

Cutaneous melanoma in Turkey: Analysis of 1157 patients in the Melanoma Turkish Study

PubMed ID: 26416068Purpose: To develop a large Turkish National Melanoma registry in order to define demographic and clinicopathologic characteristics of patients with melanoma. Methods: The data was collected from 1635 patients with melanoma through a web-based registry system in 22 centers. Herein we present the results of 1157 patients with cutaneous melanoma. Results: The patient median age was 56.4 years and 646 (55.8%) were males. The commonest subtype was superficial spreading type (357, 30.9%). The commonest primary site was the lower extremities (N=353, 30.5%). The most common Breslow thickness was 1-2 mm (361 patients, 43.5%). Only 104 (12.5%) patients had a thickness <lmm. Among 694 patients with available data, 136 (19.6%) presented with stage 4 disease while the most frequent stage was stage 3, encountered in 393 (56.6% patients). Conclusion: Our melanoma registry is the largest in our country providing a snapshot view of cutaneous melanoma and its care. Our patients presented with more advanced stages and they had worse prognosis compared to SEER database